Thank you to each and every #lupuswarrior, caregiver and advocate that stopped by our tent at the San Francisco Lupus Foundation of America, Inc. Walk To End Lupus Now 2024. We appreciated the opportunity to share about #cartcelltherapy and how it has the potential to change the landscape for #autoimmunedisease treatment! 💜🦋
Kyverna Therapeutics
Biotechnology Research
Emeryville, California 17,167 followers
Harnessing the power of cell therapy in autoimmune disease.
About us
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
- Website
-
http://kyvernatx.com
External link for Kyverna Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Emeryville, California
- Type
- Public Company
- Founded
- 2018
- Specialties
- cell therapy, autoimmune, lupus, multiple sclerosis, systemic sclerosis, scleroderma, myasthenia gravis, CAR T-cell, and stiff-person syndrome
Locations
-
Primary
Get directions
5980 Horton St
Suite 550
Emeryville, California 94608, US
Employees at Kyverna Therapeutics
Updates
-
We are proud to sponsor and attend the Lupus Foundation of America, Inc. 2024 Walk to End Lupus Now in San Francisco this Sunday, October 27th. We look forward to engaging with all of the #LupusWarriors in attendance! #CARTCellTherapy #AutoimmuneDiseases #WalkToEndLupusNow
-
-
We are excited to welcome Mert Aktar to our Board of Directors! Mert is an accomplished industry leader with over two decades of biopharmaceutical experience, melding deep technical expertise in cell and gene therapy with a proven track record in corporate strategy and business development, which will be invaluable as we seek to bring the transformative power of CAR T therapies to autoimmune patients worldwide. Welcome, Mert! #cartcelltherapy #KYV101 #autoimmunedisease
-
-
Today, we welcomed Cara Bauer (she/her) as our new Chief Human Resources Officer! Cara is an expert in Human Resource strategy, culture building and talent development, and brings more than 25 years of experience in human resources leadership, building and scaling global organizations, most recently at Kite. Welcome, Cara!
-
-
We were thrilled to have Karen Walker represent Kyverna on the panel discussion “Accelerating Access to Cell Therapies – Streamlining Research Translation and Expedited Manufacturing Technologies" at #MeetingOnTheMesa this week.
-
-
Over the weekend, Kyverna proudly supported the 2024 Walk to End Lupus Now in New York City. It was an inspiring event by Lupus Foundation of America, Inc., bringing together patients, caregivers and advocates - all united by a shared mission to make a difference for the lupus community. We're excited to continue our involvement at the San Francisco walk later this month!
-
-
Thrilled to partner with ElevateBio in developing a paradigm shift in the treatment of patients living with B cell-driven autoimmune disease. #cartcelltherapy
Kyverna Therapeutics is seeking to revolutionize the way patients with autoimmune disease are treated by leveraging ElevateBio BaseCamp’s expertise in process development and cell product manufacturing. Learn more about the strategic partnership at https://bit.ly/3N6VEVH.
-
-
We are excited to present case reports from our ongoing #cartcelltherapy trials in #stiffpersonsyndrome, #myastheniagravis, and #multiplesclerosis during our symposium at #ECTRIMS2024, together with posters on KYSA-6 and KYSA-7 study design. Read more in our press release here: https://lnkd.in/gcaMUEpN
-
-
Excited to present our latest data this Wednesday at #ECTRIMS2024 and advance the knowledge on the potential of #cartcelltherapy in neurologic #autoimmunedisease.
-
-
Today, we are excited to welcome Warner Biddle as our Chief Executive Officer. With over 30 years of global experience in senior and franchise leadership roles, Warner has an outstanding track record of steering #biotech companies through pivotal growth phases and transformative milestones. Warner’s leadership and extensive industry knowledge will be instrumental as he leads us through our next stage of growth as our clinical-stage programs in #cartcelltherapy and #autoimmunediseases continue to advance. Welcome to the team, Warner! Read more in our press release: https://lnkd.in/gxi2bWkf
-